CIRc-014 is an orally active Cyclin A/B inhibitor with a Cyclin A IC 50 of 0.05 μM, Cyclin A K d of 2.7 nM, Cyclin B IC 50 of less than 0.02 μM and Cyclin B K d of 1.0 nM. CIRc-014 activates the spindle assembly checkpoint and promotes the formation of a complex between Cyclin B and CDK2 by blocking the RxL interaction of Cyclin A/B. CIRc-014 can induce replication stress, DNA damage, mitotic arrest and apoptosis in tumor cells. CIRc-014 showed tumor growth inhibition and regression in NCI-H69 and NCI-H446 small cell lung cancer xenograft models. CIRc-014 can be used for the research of small-cell lung cancer .
Products | Products > Disease Areas > Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.